Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach ...
Suzhou Ribo Life Science Co., Ltd. ('Ribo', 06938.HK) announced that the Company has entered into a strategic collaboration ...
Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, ...
It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
GlobalData on MSN
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset
As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.
The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...
Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results